Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Turn back time: oncology trials are getting shorter

This article was originally published in Scrip

Executive Summary

It is widely accepted in the biopharmaceutical industry that clinical trial protocols are growing in complexity; many in the business bewail that the duration of trials is increasing, with patient enrollment a frequently-cited problem in clinical development.

You may also be interested in...



2017 Completed Trials: Status Quo Or No?

Trialtrove data provides window onto the landscape of industry-sponsored clinical trials completed during 2017.

2010 Scrip 100 - Little change in win, place or show

When examining the competitiveness of company pipelines, and the extent of a company's R&D commitment, it is arguably more relevant to consider the number of drug projects as reflected by clinical trials activity as opposed to the overall number of drugs in the pipeline. Clinical trial activity was assessed over the 12-month period from September 2008 to August 2009, using data from TrialTrove where trial start dates were disclosed in the public domain.

Market Insight - Clinical trials metrics tell all about pharma's R&D investment

When examining the competitiveness of company pipelines and the extent of firms' commitment to R&D, it is arguably more relevant to consider the number of drug projects as reflected by clinical trials' activity as opposed to the overall number of drugs in the pipeline. Using data from TrialTrove for the 12-month period from September 1st, 2008, to August 31st, 2009, where trial start dates were disclosed in the public domain, trial activity was analysed to determine overall rankings by industry sponsor and company R&D spend per trial.

Topics

Related Companies

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel